MECHANISM OF ACTION
RYBREVANT FASPRO™ + LAZCLUZE®
RYBREVANT FASPRO™ + LAZCLUZE® changes the biology of the disease by reducing acquired MET amplification and secondary EGFR alterations1
RYBREVANT FASPRO™* is a bispecific antibody that extracellularly targets EGFR and MET2
BLOCKS
EGFR and MET activity2
DEGRADES
EGFR and MET2
ACTIVATES
immune cell responses2,3†‡
LAZCLUZE® is a 3G TKI that intracellularly targets EGFR with4,5:
- CNS penetration
- High selectivity for mutant EGFR
TARGETS
EGFR2-5
RYBREVANT FASPRO™ + LAZCLUZE® is a chemo-free combination that achieves multitargeted inhibition of EGFR and MET with immune cell–directing activity2-5
*RYBREVANT FASPRO™ includes hyaluronidase. The effects of hyaluronidase are reversible, and permeability of the subcutaneous tissue is restored within 24 to 48 hours.2
†Trogocytosis is a process in which one cell, in this case a macrophage, physically extracts and ingests cellular material of another cell.6
‡ADCC involves the release of cytotoxic granules that cause tumor cell death.3,7
3G, third-generation; ADCC, antibody-dependent cellular cytotoxicity; CNS, central nervous system; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; TKI, tyrosine kinase inhibitor.
RYBREVANT FASPRO™ + Chemotherapy
RYBREVANT FASPRO™* + chemotherapy delivers complementary antitumor activity2,8
BLOCKS
EGFR and MET activity2
DEGRADES
EGFR and MET2
ACTIVATES
immune cell responses2,3†‡
CHEMOTHERAPY-MEDIATED
tumor cell death8,9
*RYBREVANT FASPRO™ includes hyaluronidase. The effects of hyaluronidase are reversible, and permeability of the subcutaneous tissue is restored within 24 to 48 hours.2
†Trogocytosis is a process in which one cell, in this case a macrophage, physically extracts and ingests cellular material of another cell.6
‡ADCC involves the release of cytotoxic granules that cause tumor cell death.3,7
1L, first-line.
References:
1.Hayashi H, Besse B, Lee S-H, et al. Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: updated analysis from MARIPOSA. Presented at: World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain.
2.RYBREVANT FASPRO™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
3.Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89-97. doi:10.1016/j.cllc.2022.11.004
4.LAZCLUZE® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
5.Yun J, Hong MH, Kim S-Y, et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non–small cell lung cancer. Clin Cancer Res. 2019;25(8):2575-2587. doi:10.1158/1078-0432.CCR-18-2906
6.Bettadapur A, Miller HW, Ralston KS. Biting off what can be chewed: trogocytosis in health, infection, and disease. Infect Immun. 2020;88(7):e00930-19. doi:10.1128/IAI.00930-19
7.Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-MET bispecific antibody JNJ-61186372 enhanced killing in lung cancer cells. MAbs. 2017;9(1):114-126. doi: 10.1080/19420862.2016.1249079
8.Schaer DA, Geeganage S, Amaladas N, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. Clin Cancer Res. 2019;25(23):7175-7188. doi:10.1158/1078-0432.CCR-19-0433
9.Schoch S, Gajewski S, Rothfuß J, Hartwig A, Köberle B. Comparative study of the mode of action of clinically approved platinum-based chemotherapies. Int J Mol Sci. 2020;21(18):6928. doi:10.3390/ijms21186928